康泰生物(300601.SZ)发布前三季度业绩，归母净利润4915.77万元，下降86%

Core Viewpoint - The company reported a slight increase in revenue for the first three quarters of 2025, but a significant decline in net profit, indicating potential challenges in profitability despite stable revenue growth [1] Financial Performance - The company's operating revenue for the first three quarters reached 2.063 billion yuan, representing a year-on-year increase of 2.24% [1] - The net profit attributable to shareholders was 49.1577 million yuan, showing a substantial year-on-year decrease of 86.00% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 27.8789 million yuan, reflecting a year-on-year decline of 90.82% [1] - Basic earnings per share were reported at 0.04 yuan [1]